[1]石鹏辉,王晓东,范伟光,等.保定市2019-2020年HIV-1感染者治疗前耐药分析[J].中国皮肤性病学杂志,2021,(09):1012.[doi:10.13735/j.cjdv.1001-7089.202103052]
 SHI Penghui,WANG Xiaodong,FAN Weiguang,et al.Pre-treatment Drug Resistance Analysis of HIV-1 Infected Patients in Baoding City from 2019 to 2020[J].The Chinese Journal of Dermatovenereology,2021,(09):1012.[doi:10.13735/j.cjdv.1001-7089.202103052]
点击复制

保定市2019-2020年HIV-1感染者治疗前耐药分析()
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2021年09期
页码:
1012
栏目:
性传播疾病
出版日期:
2021-09-01

文章信息/Info

Title:
Pre-treatment Drug Resistance Analysis of HIV-1 Infected Patients in Baoding City from 2019 to 2020
文章编号:
1001-7089(2021)09-1012-05
作者:
石鹏辉1王晓东1范伟光1张珍1苏苗苗1孟娟1路新利2
1.保定市人民医院,河北 保定 071000; 2.河北省疾病预防控制中心艾滋病所,河北 石家庄 050021
Author(s):
SHI Penghui1WANG Xiaodong1FAN Weiguang1ZHANG Zhen1SU Miaomiao1MENG Juan1LU Xinli2
(1.People's Hospital of Baoding City,Baoding 071000,China; 2.Hebei Provincial Center for Disease Control and Prevention,Shijiazhuang 050021,China)
关键词:
男性 性接触 HIV-1 基因亚型 耐药突变
Keywords:
Male Sexual contact HIV-1 Gene subtype Resistant mutation
分类号:
R 512.91
DOI:
10.13735/j.cjdv.1001-7089.202103052
文献标志码:
A
摘要:
目的 了解保定市HIV-1感染者治疗前耐药情况。方法 采用 In-House 方法,对血浆样本进行pol基因区扩增并测序,将拼接好的序列提交至美国斯坦福大学的HIV耐药数据库,分析 HIV-1 毒株基因亚型和耐药突变位点。结果 本研究中60例HIV-1感染者出现基因位点突变,然而只有10例出现低度以上耐药,原发耐药率为5.56%(10/180)。蛋白酶抑制剂(PIs)、核苷类逆转录酶抑制剂(NRTIs)、非核苷类逆转录酶抑制剂(NNRTIs)的原发耐药率分别是0.56%(1/180)、0.56%(1/180)和4.44%(8/180)。HIV-1耐药毒株主要分布在CRF01_AE(50.00%,5/10)、B亚型(20.00%,2/10)、B+C亚型(20.00%,2/10)和A亚型(10.00%,1/10)中。结论 保定市HIV感染者原发性耐药率高于WHO中等警戒线水平,应引起警惕,并制定有针对性的预防措施。
Abstract:
Objective To determine the presence of pre-treatment drug resistance among HIV-1 infected patients in Baoding City,Hebei Province.Methods An In-House method was used to amplify and sequence the pol gene region of HIV-1 RNA extracted from plasma samples,and the spliced sequences were submitted to the HIV drug resistance database of Stanford University in the United States to determine and analyze the gene subtypes and drug resistance mutation sites of HIV-1 strains.Results In this study,60 patients with HIV-1 infection showed mutations in gene points,but only 10 cases showed above low-level resistance,with a primary resistance rate of 5.56%(10/180).The primary drug resistance rates of protease inhibitor(PIs),nucleoside reverse transcriptase inhibitor(NRTIs),non-nucleoside reverse transcriptase inhibitor(NNRTIs)0.56%(1/180),0.56%(1/180)and 4.44%(8/180)respectively.HIV-1 drug-resistant strains were mainly distributed in CRF01-AE(50.00%,5/10),subtype B(20.00%,2/10),subtype B+C(20.00%,2/10)and subtype A(10.00%,1/10).Conclusion The primary drug resistance rate in HIV-1 infected patients of Baoding City is higher than the moderate warning level by WHO.The results should cause vigilance,and targeted preventive measures should be formulated.

参考文献/References:

[1] Lu X,Zhao H,Zhang Y,et al.HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive indivi-duals experiencing treatment failure in Hebei Province,China[J].AIDS Res Ther,2017,14(1):4.
[2] Ye J,Hao M,Xing H,et al.Characterization of subtypes and transmitted drug resistance strains of HIV among Beijing residents between 2001-2016 [J].PLoS ONE,2020,15(3):e0230779.
[3] 郑敏娜,宁铁林,高永军,等.天津市2015年HIV流行和传播的分子流行病学特征分析[J].中华流行病学杂志,2016,37(8):1142-1147.
[4] Lu X,Kang X,Liu Y,et al.HIV-1 molecular epidemiology among newly diagnosed HIV-1 individuals in Hebei,a low HIV prevalence provincein China [J].PLoS ONE,2017,12(2):e0171481.
[5] Lu X,Zhang J,Wang Y,et al.Large transmission clusters of HIV-1 main genotypes among HIV-1 individuals before antiretroviral therapy in the Hebei Province,China [J].AIDS Res Hum Retroviruses,2020,36(5):427-433.
[6] 王险峰,李峰,刘晓松,等.石家庄市2015年新确诊HIV-1感染者流行毒株的亚型分布及原发性耐药分析[J].中国艾滋病性病,2018,24(2):120-124.
[7] Zhou J,Lu X,Feng Y,et al.Genome sequence of a novel HIV-1 circulating recombinant form(CRF103_01B)identified from Hebei province,China [J].AIDS Res Hum Retroviruses,2020,36(3):234-241.
[8] 孙定勇,刘佳,许巍,等.河南省302例新确证HIV 感染者和艾滋病患者中HIV毒株基因亚型分布和原发耐药研究[J].中华预防医学杂志,2016,50(8):733-737.
[9] 金旭,卢祥婵,李剑军,等.广西过境地区抗病毒治疗HIV-1 感染者的基因型耐药分析[J].中国艾滋病性病,2016,22(8):589-592.
[10] 刘琪琛,冀永娟,马琳,等.张家口市性接触人群HIV-1遗传多样性与耐药分析[J].中国皮肤性病学杂志,2021,35(3):288-292.
[11] Lu X,Chen S,Zhao H,et al.Baseline investigation of HIV-1 primary drug resistance among newly diagnosed treatment-naïve HIV-1 individuals in Hebei,China [J].AIDS Res Hum Retroviruses,2018,34(12):1083-1089.
[12] Zhao S,Feng Y,Hu J,et al.Prevalence of transmitted HIV drug resistance in antiretroviral treatment naïve newly diagnosed individuals in China [J].Sci Rep,2018,8(1):12273.
[13] 刘大锦,冯孟贤,刘民.中国未接受抗病毒治疗的人类免疫缺陷病毒/获得性免疫缺陷综合征(HIV/AIDS)人群HIV原发耐药的Meta分析[J].北京大学学报(医学版),2015,47(3):474-482.

相似文献/References:

[1]徐顺明,谭娟,曹艳云,等.基因芯片对男性不同部位尖锐湿疣皮损中HPV型别的检测[J].中国皮肤性病学杂志,2012,(08):713.
 XU Shun-ming,TAN Juan,CAO Yan-yun,et al.Detection and Analyze of Male Condylomata Acuminata Lesions from Different Anatomical Locations with Human Papillomavirus Genotypes Gene Chips[J].The Chinese Journal of Dermatovenereology,2012,(09):713.
[2]汪丽俐,吉苏云,张淑娟,等.男性乳腺导管癌皮肤转移1例并文献复习[J].中国皮肤性病学杂志,2016,(03):284.[doi:10.13735/j.cjdv.1001-7089.201505020]
 WANG Li li,JI Su yun,ZHANG Shu juan,et al.Male Breast Ductal Cancer with Cutaneous Metastasis: A Case Report and Literature Review[J].The Chinese Journal of Dermatovenereology,2016,(09):284.[doi:10.13735/j.cjdv.1001-7089.201505020]
[3]刘会娟,刘志斌,邵明义.河南农村地区男性艾滋病合并贫血患者生存质量及影响因素分析[J].中国皮肤性病学杂志,2018,(11):1277.[doi:10.13735/j.cjdv.1001-7089.201803118]
 LIU Huijuan,LIU Zhibin,SHAO Mingyi.Study on the Quality of Life and Influencing Factors of Male AIDS Patients with Anemia in He′nan Rural Areas[J].The Chinese Journal of Dermatovenereology,2018,(09):1277.[doi:10.13735/j.cjdv.1001-7089.201803118]
[4]孙迎,袁伟,景桃勤.抗JO-1抗体阳性的男性播散性盘状红斑狼疮1例[J].中国皮肤性病学杂志,2019,(01):67.[doi:10.13735/j.cjdv.1001-7089.201803114]
 SUN Ying,YUAN Wei,JING Taoqin.A Case of Disseminated Discoid Lupus Erythematosus with Positive Anti-JO-1 Antibody and Literature Review[J].The Chinese Journal of Dermatovenereology,2019,(09):67.[doi:10.13735/j.cjdv.1001-7089.201803114]

备注/Memo

备注/Memo:
[基金项目] 河北省保定市科技计划项目(1951ZF007); 河北省自然科学基金(H2016303006)
[通信作者] 路新利,E-mail:lxlii2009@163.com
更新日期/Last Update: 2021-09-01